Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy

INTRODUCTION: Approximately, 20% of patients with pancreatic ductal adenocarcinoma have resectable disease at diagnosis. Given improvements in locoregional and systemic therapies, some patients with borderline resectable pancreatic cancer (BRPC) can now undergo successful resection. The outcomes of...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Gastrointest Surg
Main Authors: Javed, Ammar A., Wright, Michael J., Siddique, Ayat, Blair, Alex B., Ding, Ding, Burkhart, Richard A., Makary, Martin, Cameron, John L., Narang, Amol, Herman, Joseph, Zheng, Lei, Laheru, Daniel, Weiss, Matthew J., Wolfgang, Christopher, He, Jin
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6329638/
https://ncbi.nlm.nih.gov/pubmed/30242644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11605-018-3966-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares